JNJ-38877605 Struktur

JNJ-38877605

Bezeichnung:JNJ-38877605

Englisch Name:JNJ-38877605

CBNumberCB24660859

SummenformelC20H12F2N6

Molgewicht374.35

JNJ-38877605 physikalisch-chemischer Eigenschaften

JNJ-38877605 Chemische Eigenschaften,Einsatz,Produktion Methoden

Biologische Aktivität
JNJ-38877618 (OMO-1) is a potent, highly selective, and orally bioavailable Met (c-Met) kinase inhibitor with a Kd of 1.4 nM. Its IC50 values for wild-type Met (c-Met) and mutant Met (c-Met) (M1268T) were 2 nM and 3 nM, respectively.
in vivo

In vivo, JNJ-38877618(OMO-1) completely inhibited tumor growth in 3 tumor models: SNU5 MET amp gastric cancer model, U87-MG HGF autocrine glioblastoma model, and exon 14 skipping deletion mutation Hs746T gastric cancer model of MET gene. Administration of OMO-1 in combination with other drugs is well tolerated and can improve and enhance the effect of EGFR-targeted therapy. Although single-agent OMO-1 has no effect on NSCLC HCC827 EGFR, its combination with erlotinib can delay tumor recurrence.

target

< /table>